Treatment of Diabetes After Gastric Bypass With Sitagliptin (LAF33)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Columbia University
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Blandine Laferrere, Columbia University Identifier:
First received: January 13, 2012
Last updated: May 10, 2016
Last verified: May 2016
The purpose of this study is to assess whether Januvia (sitagliptin phosphate 100mg) is safe and effective for the treatment of Type 2 Diabetes in patients who have had Gastric Bypass.

Condition Intervention
Type 2 Diabetes Mellitus
Drug: Sitagliptin phosphate
Other: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess Efficacy, Safety and Tolerability of Sitagliptin Phosphate 100 mg as Treatment for Recurrent, Persistent or Newly Diagnosed Type 2 Diabetes After Gastric Bypass

Resource links provided by NLM:

Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Change in Postprandial Glucose Levels in Patients with Type 2 Diabetes After Gastric Bypass Surgery [ Time Frame: Baseline and 6 weeks ] [ Designated as safety issue: No ]
    Sitagliptin 100 mg/d given for 6 weeks will lower postprandial glucose levels during a 200 kcal test meal compared to placebo in patients with type 2 diabetes after gastric bypass surgery.

Secondary Outcome Measures:
  • Change in Satiety in Patients with Type 2 Diabetes After Gastric Bypass Surgery [ Time Frame: Baseline and 6 weeks ] [ Designated as safety issue: No ]
    Sitagliptin 100 mg/d for 6 weeks will increase satiety more than placebo following a 200 kcal standard meal in patients with type 2 diabetes after gastric bypass surgery

  • Occurrence of Side Effects In Relation to Sitagliptin [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
    Sitagliptin 100 mg/d for 6 weeks will not be associated with serious side effect and /or more side effects than placebo.

Estimated Enrollment: 32
Study Start Date: July 2012
Estimated Study Completion Date: October 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Sitagliptin phosphate
100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
Drug: Sitagliptin phosphate
100 mg/day orally
Other Name: Januvia
Placebo Comparator: Placebo
1 Placebo pill / day PO once a day for 4-5 weeks
Other: Placebo
1 Placebo Pill per day

Detailed Description:
Januvia (sitagliptin phosphate 100mg) is an FDA approved medication for the treatment of Type 2 Diabetes. Sitagliptin works by inhibiting the Dipeptidyl peptidase-4 enzyme, resulting in increased active glucagon-like peptide-1 (GLP-1) levels. GLP-1 is an incretin which increases post-prandial insulin secretion. Because Gastric Bypass has also been shown to increase GLP-1 levels, this study seeks to determine the additional effect of DDP-4 inhibition on glucose control in patients who have elevated incretin levels post Gastric Bypass. The study will also assess if Januvia (Sitagliptin phosphate) is safe and well tolerated in patients after Gastric Bypass.

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must be a resident of the NYC metropolitan area or be able to come for emergency unscheduled and regular weekly meetings in Manhattan.
  • HbA1c ≥ 6.5% and ≤ 8.5 % or a fasting glucose ≥ 126 mg/dL or a random glucose ≥ 200 mg/dL at least 12 months after GBP surgery confirmed by central laboratory.
  • Subject is capable and willing to give informed consent.
  • Subject is otherwise in good general health, based on medical history and physical examination.
  • Subject is a non smoker for at least 6 months prior to study start
  • Female subjects of child bearing potential must use oral, injected or implanted hormonal methods of contraception from at least the commencement of their last normal period prior to the first administration of the challenge agent. Subjects using hormonal contraception should use a barrier method in addition from the first administration of challenge agent until their next normal period following the end of the study.

Exclusion Criteria:

  • History of type 1 diabetes
  • Female subject is pregnant or breastfeeding.
  • Recent (< 30 days) or simultaneous participation in another clinical trial.
  • Any situation that can compromise the study, including serious illness or a predictable lack of cooperation from the subject.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01512797

Contact: Yelana Zubatov, MD (212) 523-3357
Contact: Marlena Holter (212) 851-5581

United States, New York
New York Obesity Nutrition Research Center, Columbia University Recruiting
New York, New York, United States, 10032
Contact: Marlena Holter, BA    212-851-5581   
Principal Investigator: Blandine Laferrere, MD         
Sponsors and Collaborators
Blandine Laferrere
Merck Sharp & Dohme Corp.
Principal Investigator: Blandine Laferrere, MD New York Obesity Nutrition Research Center
  More Information

Additional Information:
Responsible Party: Blandine Laferrere, Associate Professor of Medicine, Columbia University, Columbia University Identifier: NCT01512797     History of Changes
Other Study ID Numbers: AAAO1107 
Study First Received: January 13, 2012
Last Updated: May 10, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by Columbia University:

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Sitagliptin Phosphate
Dipeptidyl-Peptidase IV Inhibitors
Enzyme Inhibitors
Hormones, Hormone Substitutes, and Hormone Antagonists
Hypoglycemic Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Protease Inhibitors processed this record on May 26, 2016